Arovella Therapeutics Ltd (ASX:ALA) CEO Michael Baker speaks with Proactive following the company’s successful placement which raised $4.1 million. ALA also aims to raise an extra $1 million via a share purchase plan. The funds will allow the biotechnology company, which is focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, to fund the development of ALA-101 towards clinical trials and to enhance Arovella’s iNKT cell pipeline.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
